Adtec Healthcare celebrates yet another RCT publication

 

Adtec Healthcare celebrates another prospective, randomized and placebo-controlled trial (RCT) publication featuring our cold plasma medical device for the treatment of chronic wounds. The clinical trial conducted at the Essen University Medical Center in Germany and led by Professor Joachim Dissemond discusses the strong benefit of using the Adtec SteriPlas to treat chronic wounds. This is our first RCT measuring wound healing rates with respect to overall wound size using cold plasma.

The study consisting of three groups (Group 1 - plasma 1x/week, Group 2- plasma 3x/week and Group 3 - placebo 1x/week) shows the significant wound size reduction when using cold plasma vs placebo. Not surprisingly, Groups 1 and 2 led an astonishing 63.0% and 46.8% reduction in wound size for chronic wound patients, whereas Group 3 (placebo-treated) patients had increased in wound size by 17.5% larger.

The full publication can be viewed here: https://onlinelibrary.wiley.com/doi/epdf/10.1111/ddg.14294

The rich data of the RCT further demonstrates why our cold plasma medical device, the Adtec SteriPlas, continues to lead the way for cold plasma medicine by accelerating healing in non-healing and problematic wounds with the strong advantage of no side effects. The use of the Adtec SteriPlas is simple – a quick supplement to your standard treatment program for your patients.

 

Contact us at info@adtecplasma.com to learn more about our medical device and how to obtain this in your clinic.


Leading cold plasma medical device

 

The Adtec SteriPlas is the leading cold plasma medical device used to manage the infection in chronic wounds, surgical site infections and to treat dermatological conditions such as acne and actinic keratoses.

 

With our wide clinical trials and publications bibliography, we are proud to state its strong antibacterial efficacy regardless of the type of bacteria or its resistance profile. There have been no side effects reported with the use of our medical device since it is safe, painless to touch and an effective method of treating patients from conventional therapies.


EWMA 2020 virtual conference

Adtec Healthcare prepares for its first virtual conference of 2020!

 

Typically, exhibiting at the European Wound Management Association (EWMA) conference would mean welcoming you to our booth but due to the coronavirus restrictions this year’s conference will be fully virtual.
As many prefer to see us and our medical device in person we are preparing our best to still meet these needs. We will have a wide library of information, videos, presentations and clinical evidence that you can freely visit on the exhibition portal. You will also be able to talk with us using the “chat” system.

Other than being separated from each other by computer screens, Adtec Healthcare’s presence will still be known as we welcome you to our virtual booth.

 


New Actinic Keratoses clinical trial publication release

Congratulations Professor Alexander Rösch and his team at the Department of Dermatology at the University Hospital Essen for their recent clinical trial publication. The study “Efficacy of cold atmospheric plasma versus diclofenac 3% gel in patients with actinic keratoses: a prospective,  randomized, and rater-blinded study (ACTICAP)” can be found here.

Their clinical trial began in 2017 and its purpose was to test the efficacy of our medical device, the Adtec SteriPlas on actinic keratoses patients in comparison to those treated with Diclofenac 3% gel. The clinical efficacy of this modality is comparable to that of Diclofenac gel. However, unlike Diclofenac, cold atmospheric plasma showed no major side effects. Thus, this modality might be especially well-suited for patients who require nontoxic treatment options, particularly immunocompromised patients and those with extensive field cancerization. This continues to be one of our strongest and most favoured characteristics of the Adtec SteriPlas: no side effects.

We encourage you to read the clinical trial publication and welcome any questions that you have.

#actinickeratoses #actinickeratosis #skin #dermatology #coldplasma #kaltesplasma #clinicaltrial #sideeffects


Update to clinical section on our website

 

We have recently updated the clinical section of our website to illustrate the proven antibacterial efficacy of the Adtec SteriPlas: http://adtecplasma.com/clinical.html

 

Chronic and complex wounds that are often stalled by biofilm such as diabetic foot ulcers may find difficulty to heal using conventional treatment therapies. This also applies to deep surgical site infections in cardiac patients where the morbidity rate is usually high. Using our medical device to treat these complex conditions has shown to offer promising hope leading to full healing, even if biofilm has persisted to deteriorate the wound before. Patients have been saved from amputations and given a better Quality of Life.

 

Other than diabetic foot ulcers and surgical site infections, we have collected strong clinical efficacy for the treatment of dermatology skin conditions. We encourage you to contact us at info@adtec.eu.com to learn about the myriad of benefits that our leading cold plasma medical device can offer your patients.


Two new publications for our cold plasma treating surgical site infections

Congratulations to Dr Heinrich Rotering for two publications released this year documenting the treating of surgical site infections and infected drivelines with the Adtec SteriPlas.

 

His first publication this year, “Cold atmospheric plasma and advanced negative pressure wound therapy” features the unique combination of our Adtec SteriPlas medical device with NPWT. A link to the purchase of this paper can be found in the The Journal for Cardiac, Thoracic and Vascular Surgery on Springer Link: https://link.springer.com/article/10.1007/s00398-019-00355-0?fbclid=IwAR0O5Vh6i8QWtTuR7s8ha-10xwoJtd5n_YNY_NM5rQkDT8a8B9p9WWEKxBc

 

His second publication this year, “Preliminary Results of a New Treatment Strategy for Relapsed Left Ventricular Assist Device-Specific Infections” discusses how relapsed ventricular assist device-specific infections are associated with high morbidity, mortality, and hospital costs. A new combination of cold atmospheric plasma and special dressing technique with negative pressure wound therapy with an additional underlay of carbon cloth and hypochlorite rinsing solutions has been developed and reported in his study.

https://pubmed.ncbi.nlm.nih.gov/32169499/?fbclid=IwAR3jA0jwGoaeaui8tUQVbsw-snidQ0SivtareKAOnRntAxh1_38J7z2s8LA

 

Dr Rotering has already demonstrated the proven antibacterial efficacy of the Adtec SteriPlas for the treatment of deep surgical site infections and infected drivelines in previous conference presentations, and these papers further demonstrate the accelerated healing potential with the unique combination of the two treatment therapies.

 

We encourage you to read these publications to learn the benefits of the Adtec SteriPlas for the treatment of complicated and stalled wounds and surgical site infections.


Medical conferences postponed for 2020 due to COVID restrictions

With the ongoing COVID-19 lockdown, many medical conferences that we would usually exhibit have been postponed. This year’s conferences include the Malvern Diabetic Foot conference which is now postponed to 2021, the EWMA conference which is now postponed to 18th-20th November and the DFSG conference which will now be a virtual conference.

For customers and friends that we had already planned to meet at the conferences and can now no longer attend, we are happy to meet with you in person once the lockdown restrictions have been lifted. Until then, we are still contactable via our normal communication routes and welcome any discussions.

We wish everyone in our network to be safe and well.


Adtec Healthcare's new project with Hull York Medical School testing gas plasma on Osteomyelitis bone infections.

 

We are excited to announce the study “Gas Plasma for the Prevention and Management of Osteomyelitis Biofilms” has now begun at the Hull York Medical School. The study led by Dr Angela Oates and funded by the National Biofilms Innovation Centre will seek to test the efficacy of our gas plasma system on osteomyelitis bone infections using our PlasmaTact device. This project will develop a novel laboratory testing model to evaluate and optimise plasma treatment for osteomyelitis biofilm infections.

 

 

We have already demonstrated that our gas plasma medical device, the Adtec SteriPlas, has proven antibacterial efficacy and accelerated healing in problematic and non-healing wounds with strong evidence collected from our extensive library of clinical trials and publications. This includes diabetic foot ulcers which are often complicated by biofilm. Over the course of its existence it has shown that no side effects have been reported which offers patients a safe and reliable treatment option. It has also shown that a 2-minute treatment time is sufficient to achieve exceptional results and that it is also a broad spectrum antibacterial with the ability to kill a wide range of Gram-negative and Gram-positive bacterial superinfections.

 

The PlasmaTact utilizes the same gas plasma technology from the Adtec SteriPlas. The main difference between the two devices is that the PlasmaTact offers a smaller handheld style treatment area of 1cm2 (vs 12cm2 with the SteriPlas) and offers users the ability to change the power output settings (vs the fixed settings with the SteriPlas).

 

Osteomyelitis (OM) is biofilm infection of the bone and is a common and costly complication in diabetic foot ulcer (DFU) patients often resulting in amputations. Long-term antimicrobial therapy is widely used as a primary treatment for OM or as an adjunct to surgical approaches however, there is a failure rate of up to 35% and an associated increasing prevalence of antimicrobial resistance. There is an urgent clinical need to develop alternative non-antimicrobial approaches to treat infections, and currently there is a lack of credible alternatives in the market for the treatment of OM.

 

Evaluating the efficacy of gas plasma in OM represents unique challenges as both the biofilm growth and physical characteristics of OM bone will affect the delivery and activity of the plasma. In vitro biofilm model systems offer a means by which rapid, costs effective and standardised evaluation of anti-biofilm treatments can be undertaken.

 

The PATROL project is a new and exciting collaborative project between Adtec Healthcare and Dr Angela Oates of the University of Hull Wound Healing Group which is supported by NBIC PoC Award. The overall aim of this project is to develop an osteomyelitis biofilm infection model to support the optimisation and evaluation of a cold plasma technology for the management and prevention of OM.

 

This collaborative project represents the first phase of the novel utilisation of Adtec SteriPlas to treat OM or as an adjunct current therapy. Successful translation of this technology to treat OM will reduce antimicrobial usage and associated OM amputations, reducing NHS costs and ultimately improving patient outcomes.

 

#osteomyelitis #biofilm #boneinfection #infection #antimicrobial #antimicrobialresistance #amputation #plasma #gasplasma #coldplasma #kaltesplasma #NBIC #universityofhull #podiatry #diabeticfootulcer #diabeticfoot #diabetes #hullyorkmedicalschool


Adtec Healthcare confirms attendance for 3rd conference in 2020

 

Adtec Healthcare looks forward to exhibiting at the Diabetic Foot Study Group (DFSG) conference in Bratislava, Slovakia between 18-20 September 2020.

You can find us at booth 13 in the exhibition hall where our staff will be ready to welcome you. We will also have our flagship medical device, the Adtec SteriPlas, live on demonstration to show you how easy it is to treat diabetic foot ulcers.

 

 

#plasma #coldplasma #kaltesplasma #gasplasma #DFSG #DFSG2020 #diabeticfootulcer #wound #woundcare #woundhealing #wundkongress #wund #medicaldevice #DFSG #DFSG2020


Adtec Healthcare exhibiting at two leading wound conferences this year

Adtec Healthcare looks forward to exhibit at the European Wound Management Association (EWMA) conference and The Malvern Diabetic Foot Conference in May 2020. As the two conferences will be running on the same dates (13th-15th May ’20), we will have teams exhibiting at both conferences so we can meet with you at whichever conference you attend.

 

We will have our medical device live on display at both exhibitions and look forward to inviting you to our booth to give a demonstration on its ease of use to achieve remarkable results.

 

 

#EWMA #EWMA2020 #MalvernDFU #Malvern2020 #wound #wundkongress #coldplasma #kaltesplasma #gasplasma #plasma #exhibition #woundcare #surgicalsiteinfection #preventSSI #SSIprevention